Spark Investment Management LLC Invests $2.06 Million in Sarepta Therapeutics Inc (SRPT)
Spark Investment Management LLC purchased a new position in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 15,600 shares of the biotechnology company’s stock, valued at approximately $2,062,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of SRPT. Xact Kapitalforvaltning AB lifted its position in Sarepta Therapeutics by 5.7% in the second quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the biotechnology company’s stock valued at $1,216,000 after buying an additional 500 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Sarepta Therapeutics by 2.7% during the first quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock worth $1,478,000 after purchasing an additional 530 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Sarepta Therapeutics by 0.5% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 145,854 shares of the biotechnology company’s stock worth $19,279,000 after purchasing an additional 709 shares in the last quarter. SeaCrest Wealth Management LLC lifted its position in shares of Sarepta Therapeutics by 59.0% during the second quarter. SeaCrest Wealth Management LLC now owns 2,326 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 863 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in shares of Sarepta Therapeutics by 11.0% during the second quarter. Commonwealth Equity Services LLC now owns 8,989 shares of the biotechnology company’s stock worth $1,188,000 after purchasing an additional 892 shares in the last quarter. 90.01% of the stock is owned by institutional investors.
In related news, CEO Douglas S. Ingram purchased 16,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average cost of $125.26 per share, with a total value of $2,004,160.00. Following the transaction, the chief executive officer now owns 399,250 shares of the company’s stock, valued at approximately $50,010,055. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard Barry sold 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $130.34, for a total value of $9,775,500.00. Following the completion of the transaction, the director now directly owns 3,170,432 shares in the company, valued at $413,234,106.88. The disclosure for this sale can be found here. Insiders sold a total of 158,782 shares of company stock valued at $21,237,444 in the last 90 days. 7.90% of the stock is owned by company insiders.
Shares of NASDAQ:SRPT traded up $2.55 during midday trading on Friday, hitting $152.76. 1,199,217 shares of the stock were exchanged, compared to its average volume of 810,309. The company has a quick ratio of 9.89, a current ratio of 10.88 and a debt-to-equity ratio of 0.62. Sarepta Therapeutics Inc has a twelve month low of $42.97 and a twelve month high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.99). The company had revenue of $73.53 million for the quarter, compared to analysts’ expectations of $71.53 million. Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The company’s revenue for the quarter was up 110.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.48) EPS. research analysts predict that Sarepta Therapeutics Inc will post -3.69 EPS for the current year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Further Reading: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.